Browse by Series:

FDA Approval in Rare Leukemias, Priority Reviews in MSI-H Cancers and Merkel Cell Carcinoma, and More

Gina Columbus
Published: Thursday, Dec 01, 2016

Slider Left
Slider Right
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication